228412-69-9

Upstream product

• 51-21-8 5-fluorouracil 
• 228412-66-6 2-acetoxy-N-<4-O--3-nitrobenzyloxycarbonyl>glycine methyl ester 
• 148580-01-2 (2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-[2-nitro-4-(4-nitro-phenoxycarbonyloxymethyl)-phenoxy]-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 228412-64-4 N-<4-O--3-nitrobenzyloxycarbonyl>serine methyl ester 

Downstream Products

• 228412-70-2 N-<4-O--3-nitrobenzyloxycarbonyl>-2-(5-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)glycine methyl ester 

Relevant academic research and scientific papers

Synthesis of self-immolative glucuroenide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy

The synthesis of three novel potential glucuronide-based prodrugs for antibody-directed enzyme prodrug therapy (ADEPT) is described. These prodrugs were designed to be activated at the tumour site by -glucuronidase to afford the corrresponding anticancer agent, 5-FU. The structural pattern of these compounds includes a self-immolative spacer between the glucuronyl residue and the N1 of 5-FU. Three types of spacers have been elaborated which, after enzymic hydrolysis, spontaneously decompose to deliver an unstable N1 aminal 5-FU derivative and, from there, the cytotoxic drug. All potential prodrugs were stable and proved to be excellent substrates of E. coll in in vitro experiments.